Cargando…
Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study
BACKGROUND: During ongoing COVID-19 pandemic, researchers worked enormously to develop effective vaccines against COVID-19 infection. Two Indian-made vaccines [Covishield (ChAdOx1 nCoV-19) and Covaxin] were granted Emergency Use Authorization. India launched its COVID-19 vaccination drive starting w...
Autores principales: | Kamal, Deep, Thakur, Vaidehi, Nath, Navneet, Malhotra, Tarun, Gupta, Aditya, Batlish, Rajesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313058/ https://www.ncbi.nlm.nih.gov/pubmed/34334895 http://dx.doi.org/10.1016/j.mjafi.2021.06.014 |
Ejemplares similares
-
Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
por: Devi, Leimapokpam Sumitra, et al.
Publicado: (2022) -
Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield) in patients with liver cirrhosis
por: Katiyar, Harshita, et al.
Publicado: (2022) -
Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
por: Goel, Amit, et al.
Publicado: (2022) -
Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
por: Sivaramakrishnan, Prakash, et al.
Publicado: (2022) -
Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
por: Singh, Amandeep, et al.
Publicado: (2022)